Lower blood pressure-induced renal hypoperfusion promotes cisplatin-induced nephrotoxicity

Tomohiro Mizuno, Takahiro Hayashi, Yuka Shimabukuro, Maho Murase, Hiroki Hayashi, Kazuhiro Ishikawa, Kazuo Takahashi, Yukio Yuzawa, Shigeki Yamada, Tadashi Nagamatsu

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Background and Aims: Cisplatin-induced nephrotoxicity primarily occurs in the proximal tubules, and tubular injuries reduce glomerular filtration rates. Lower blood pressure causes renal hypoperfusion, which promotes ischemic acute kidney injury (AKI). Our study examined the relationship between lower blood pressure-induced renal hypoperfusion and cisplatin-induced nephrotoxicity. Methods: The relationship between cisplatin use and hypoalbuminemia is not clear. This study consisted of Japanese patients who received cisplatin as the first-line chemotherapy at Fujita Health University Hospital from April 2006 to December 2012. Hypoalbuminemia was defined as serum albumin levels ≤3.5 mg/dl. Results: Patients who experienced lower blood pressure during chemotherapy were included in the lower blood pressure group (n = 229), and those who did not were included in the normal blood pressure group (n = 743). Total cisplatin dose in the normal blood pressure and lower blood pressure groups was 58.9 ± 23.8 and 55.0 ± 20.4 mg/m2, respectively. The rate of severe nephrotoxicity was higher and overall survival was shorter in the lower blood pressure group than in the normal blood pressure group. In a multivariable analysis, lower blood pressure significantly correlated with hypoalbuminemia. Conclusions: To prevent ischemic AKI, nutrition and cachexia controlling are important parts of cancer treatment.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalOncology (Switzerland)
Issue number6
Publication statusPublished - 14-06-2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Lower blood pressure-induced renal hypoperfusion promotes cisplatin-induced nephrotoxicity'. Together they form a unique fingerprint.

Cite this